Population

75 adolescent and adult women (15-47 years old), phototypes III to VI, with mild to moderate acne and at least one post-inflammatory hyperpigmentation

Application of KERACNYL serum

Application once or twice a day to the face for 3 months
With (n= 35) or without (n=39) associated anti-acne medication

Evaluation criteria

• Clinical scoring of efficacy on hyperseborrhea (4-point scale)
• Clinical scoring of efficacy on acne lesions (GEA score)
• Evaluation of efficacy on post-inflammatory hyperpigmentation (IGA score)
• Evaluation of clinical response
• Illustrative photographs (5-point scale)
• Perceived efficacy
• Skin tolerance
   

Results

Without associated anti-acne medication:

• Significant improvement in hyperseborrhea at 3 months
• Significant decrease in GEA score at 3 months
• Improvement in acne severity perceived by 80.6% of patients at 3 months
• Significant improvement in the severity of post-inflammatory hyperpigmentation (PIH) lesions at 3 months

With associated anti-acne medication:

• Good to very good skin tolerance in combination with medicinal treatments in 93.4% of patients at 3 months

Conclusion

• Reduction of excess sebum
• Anti-blemish efficacy
• Efficacy on post-inflammatory hyperpigmentation
• Good to very good tolerance in combination with anti-acne medicinal treatments